Friday, 16 October 2026European Markets

ROTHSCHILD & CO Stock Bearish Momentum With A 16% Drop In The Last 5 Sessions

Loading stream...

rothschild & co (roth.pa), a global advisory and investment firm, is currently experiencing a striking drop on the cac 40 index. over five trading sessions, its stock price declined 16.68% from eur46.45 to eur38.70 despite overall cac 40 growth of 0.65%; suggesting it may have an especially vulnerable position within its market.

rothschild & co's stock performance

rothschild & co's stock has seen a steep 19.46% decline since reaching its 52-week high of eur48.05. however, key financial indicators of rothschild & co remain positive despite this steep decrease. their trailing twelve month earnings per share (eps) stands at eur8.29 which indicates steady profitability and their price-to-earnings ratio stands at 4.67 which indicates investors are paying eur4.67 for every euro of earnings - a fair valuation given industry standards.

return on equity analysis

return on equity (roe) of 21.02% for the past twelve months indicates a solid return for shareholders' investments; however, given recent fluctuations in stock price performance and their causes may warrant additional scrutiny by potential investors.

investor response and market challenges

rothschild & co's share price drop could be due to investor response to operational or market challenges the company is encountering; further investigation would help shareholders understand current market performance more accurately.

financial indicators vs market performance

rothschild & co is showing solid financial indicators, yet the stark disparity between its stock performance and that of cac 40 index emphasizes the need for investor vigilance. financial literacy requires keeping abreast of news related to specific companies or industries when dealing with equity investments - showing that individual company performance does not always equate to positive market response.

more news about rothschild & co (roth.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com